Amneal (NYSE: AMRX) director converts RSUs to shares and gets new grant

Rhea-AI Filing Summary

Amneal Pharmaceuticals director Yanai Shlomo increased his equity stake through stock-based compensation activity. He exercised 34,819 restricted stock units into the same number of shares of Class A Common Stock and did not sell any shares. Following this exercise, he directly owns 320,804 shares. In a separate transaction, he also received a grant of 19,824 new restricted stock units, each representing a contingent right to receive one share of Class A Common Stock.

Insider Trade Summary

34,819 shares exercised/converted

Mixed 3 txns

Insider Yanai Shlomo

Role null

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	34,819	$0.00	--
Exercise	Class A Common Stock	34,819	$0.00	--
Grant/Award	Restricted Stock Units	19,824	$0.00	--

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Class A Common Stock — 320,804 shares (Direct, null)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On May 6, 2025, the reporting person was granted 34,819 restricted stock units vesting on May 7, 2026. Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.

Key Figures

RSUs exercised: 34,819 shares Shares held after exercise: 320,804 shares New RSU grant: 19,824 units +1 more

4 metrics

RSUs exercised 34,819 shares Restricted stock units converted into Class A Common Stock on May 7, 2026

Shares held after exercise 320,804 shares Direct Class A Common Stock holdings following transactions

New RSU grant 19,824 units Restricted stock units granted on May 6, 2026

RSU-to-share ratio 1:1 Each RSU represents one share of Class A Common Stock

Key Terms

Restricted Stock Units, Class A Common Stock, derivative security

3 terms

Restricted Stock Units financial

"The filing reports transactions in "Restricted Stock Units" that convert into Class A Common Stock."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Class A Common Stock financial

"Shlomo exercised restricted stock units into shares of "Class A Common Stock.""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

derivative security financial

"The exercise transaction is described as "Exercise or conversion of derivative security.""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yanai Shlomo

(Last) (First) (Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

400 CROSSING BOULEVARD

(Street)

BRIDGEWATER NEW JERSEY 08807

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	05/07/2026		M		34,819	A	(1)	320,804	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	05/07/2026		M			34,819	(2)	(2)	Class A Common Stock	34,819	$0	0	D
Restricted Stock Units	(1)	05/06/2026		A		19,824		(3)	(3)	Class A Common Stock	19,824	$0	19,824	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

2. On May 6, 2025, the reporting person was granted 34,819 restricted stock units vesting on May 7, 2026.

3. Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.

Remarks:

	/s/ Denis Butkovic, Attorney-in-Fact	05/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Amneal (AMRX) director Yanai Shlomo report?

Director Yanai Shlomo reported exercising 34,819 restricted stock units into Class A Common Stock and receiving a separate grant of 19,824 new restricted stock units. These transactions increased his direct equity exposure without any reported open-market share sales.

Did Yanai Shlomo buy or sell Amneal (AMRX) shares on the market?

The filing shows no open-market buying or selling. Instead, Shlomo exercised 34,819 restricted stock units into common shares and received 19,824 additional restricted stock units as a grant, both classified as acquisitions rather than market trades.

How many Amneal (AMRX) shares does Yanai Shlomo hold after these transactions?

After exercising restricted stock units, Yanai Shlomo directly holds 320,804 shares of Amneal Class A Common Stock. This figure reflects his position following the May 7, 2026 equity compensation-related transactions reported in the Form 4.

What are restricted stock units in the Amneal (AMRX) Form 4 filing?

In this filing, each restricted stock unit represents a contingent right to receive one share of Amneal’s Class A Common Stock. Units typically vest over time, and upon vesting, they convert into common shares, as seen with the 34,819 units Shlomo exercised.

Was a new equity award granted to Yanai Shlomo by Amneal (AMRX)?

Yes. The Form 4 reports that Yanai Shlomo was granted 19,824 restricted stock units. This award is classified as a grant or other acquisition and adds to his stock-based compensation, potentially converting into the same number of Class A shares when vested.